Abeona Therapeutics Inc (ABEO.OQ)
20.90USD
20 Apr 2018
$0.85 (+4.24%)
$20.05
$20.30
$21.65
$20.10
201,372
264,708
$22.70
$4.55
About
Overall
| Beta: | 1.29 |
| Market Cap(Mil.): | $977.60 |
| Shares Outstanding(Mil.): | 46.78 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ABEO.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 188.22 | 33.60 |
| EPS (TTM): | -0.65 | -- | -- |
| ROI: | -19.80 | -0.74 | 13.19 |
| ROE: | -20.30 | -2.80 | 15.00 |
BRIEF-Abeona Therapeutics Receives Orphan Drug Designation In The European Union For ABO-202 Gene Therapy Program In Batten Disease
* ABEONA THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR ABO-202 GENE THERAPY PROGRAM IN BATTEN DISEASE Source text for Eikon: Further company coverage:
BRIEF-Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer
* ABEONA THERAPEUTICS APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER
BRIEF-Abeona Therapeutics Appoints Carsten Thiel As Chief Executive Officer
* TIMOTHY J. MILLER WILL REMAIN PRESIDENT AND ASSUME POSITION OF CHIEF SCIENTIFIC OFFICER Source text for Eikon: Further company coverage:
BRIEF-Abeona Therapeutics Reports Q4 Loss Per Share $0.19
* ABEONA THERAPEUTICS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS
BRIEF-Abeona Receives FDA Rare Pediatric Disease Designation For ABO-202 Gene Therapy Program In CLN1 Disease
* ABEONA THERAPEUTICS RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION FOR ABO-202 GENE THERAPY PROGRAM IN CLN1 DISEASE
BRIEF-Abeona Receives FDA Orphan Drug Status For Gene Therapy To Treat Rare Disease In Newborns
* ABEONA THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ABO-202 GENE THERAPY PROGRAM IN INFANTILE BATTEN DISEASE
BRIEF-Abeona Therapeutics Says Gene Therapy ABO-101 Is Well Tolerated
* ABEONA THERAPEUTICS REPORTS ON INITIAL SAFETY AND BIOPOTENCY SIGNALS IN MPS IIIB GENE THERAPY CLINICAL TRIAL
BRIEF-Abeona Receives FDA Regenerative Medicine Advanced Therapy Status For Experimental Gene Therapy For Rare Skin Disorder
* ABEONA RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR EB-101 GENE THERAPY IN EPIDERMOLYSIS BULLOSA
BRIEF-Abeona Q3 loss per share $0.13
* Abeona reports third quarter 2017 financial results and recent business highlights
Competitors
| Price | Chg | |
|---|---|---|
| Amgen, Inc. (AMGN.OQ) | $171.56 | -1.37 |
| Curagen Corp (CRGN.OQ) | -- | -- |
| OSI Pharmaceuticals, Inc. (OSIP.OQ) | -- | -- |
| Bristol-Myers Squibb Co (BMY.N) | $51.17 | -0.44 |
| Bristol-Myers Squibb Co (BMYMP.PK) | $1,306.55 | -- |
| Sanofi SA (SASY.PA) | €65.28 | -0.32 |
| Agenus Inc (AGEN.OQ) | $3.78 | +0.02 |
| Poniard Pharmaceuticals, Inc. (PARD.PK) | $0.05 | 0.00 |
| NanoCarrier Co., Ltd. (4571.T) | ¥703 | +14.00 |
| Enzon Pharmaceuticals Inc (ENZN.PK) | $0.26 | -0.00 |
Estimates